Clinical pharmacokinetics of alpha 1-antitrypsin in homozygous PiZ deficient patients

Clin Pharmacokinet. 1992 Aug;23(2):161-8. doi: 10.2165/00003088-199223020-00007.

Abstract

A pharmacokinetic study of alpha 1-antitrypsin (ATT) was performed in 2 groups of homozygous PiZ-deficient patients (treated and untreated) and 1 group of healthy volunteers. The distribution of the 131I-labelled protein corresponds to a 3-compartment model. The intravenously administered protein diffused quickly to the extravascular compartment where some retention occurred. No significant difference in AAT metabolism was observed between the 3 groups. The half-life of the injected protein is slightly longer than 2.5 days. The AAT protein was not stored. These results confirm the observations collected during the clinical trials. That is, a weekly infusion is necessary to obtain stable serum AAT concentrations. Monthly infusions are unable to maintain a 'plateau' phase. The periodicity may be limited to every 2 weeks.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Analysis of Variance
  • Female
  • Half-Life
  • Homozygote
  • Humans
  • Injections, Intravenous
  • Male
  • Metabolic Clearance Rate
  • Middle Aged
  • Phenotype
  • alpha 1-Antitrypsin / administration & dosage
  • alpha 1-Antitrypsin / pharmacokinetics*
  • alpha 1-Antitrypsin Deficiency*

Substances

  • alpha 1-Antitrypsin